Cases & Deals

OticPharma licenses novel treatment for ear infections from Otodyne

Clients OticPharma, Inc.

Jones Day represented OticPharma, Inc. in the acquisition of worldwide rights of Otodyne and its affiliate SDRI to OTO-101, a novel treatment for otitis media based upon spraying a surfactant composition into the nose. OticPharma will take control of the IND for the treatment and continue to develop, seek regulatory approval for, and commercialize the treatment method.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.